Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Intellia Therapeutics Inc has a consensus price target of $81.36 based on the ratings of 32 analysts. The high is $182 issued by HC Wainwright & Co. on November 5, 2021. The low is $29 issued by Citigroup on May 10, 2024. The 3 most-recent analyst ratings were released by RBC Capital, Jones Trading, and Stifel on September 19, 2024, September 17, 2024, and September 11, 2024, respectively. With an average price target of $53 between RBC Capital, Jones Trading, and Stifel, there's an implied 146.01% upside for Intellia Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Intellia Therapeutics (NASDAQ:NTLA) was reported by RBC Capital on September 19, 2024. The analyst firm set a price target for $54.00 expecting NTLA to rise to within 12 months (a possible 150.65% upside). 22 analyst firms have reported ratings in the last year.
The latest analyst rating for Intellia Therapeutics (NASDAQ:NTLA) was provided by RBC Capital, and Intellia Therapeutics reiterated their outperform rating.
The last upgrade for Intellia Therapeutics Inc happened on March 14, 2023 when BMO Capital raised their price target to $57. BMO Capital previously had a market perform for Intellia Therapeutics Inc.
The last downgrade for Intellia Therapeutics Inc happened on February 23, 2024 when Goldman Sachs changed their price target from N/A to $32 for Intellia Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intellia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intellia Therapeutics was filed on September 19, 2024 so you should expect the next rating to be made available sometime around September 19, 2025.
While ratings are subjective and will change, the latest Intellia Therapeutics (NTLA) rating was a reiterated with a price target of $54.00 to $54.00. The current price Intellia Therapeutics (NTLA) is trading at is $21.54, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.